Benitec Biopharma Inc. BNTC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.80M | 28.23M | 29.78M | 27.66M | 23.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.19M | 46.60M | 48.35M | 45.78M | 41.77M |
| Operating Income | -51.19M | -46.60M | -48.35M | -45.78M | -41.77M |
| Income Before Tax | -45.55M | -41.54M | -44.11M | -41.82M | -37.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.55 | -41.54 | -44.11 | -41.82 | -37.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.55M | -41.54M | -44.11M | -41.82M | -37.92M |
| EBIT | -51.19M | -46.60M | -48.35M | -45.78M | -41.77M |
| EBITDA | -51.13M | -46.54M | -48.30M | -45.72M | -41.70M |
| EPS Basic | -0.97 | -0.93 | -1.06 | -1.06 | -1.03 |
| Normalized Basic EPS | -0.61 | -0.58 | -0.66 | -0.68 | -0.66 |
| EPS Diluted | -0.97 | -0.93 | -1.06 | -1.06 | -1.03 |
| Normalized Diluted EPS | -0.61 | -0.58 | -0.66 | -0.68 | -0.66 |
| Average Basic Shares Outstanding | 186.32M | 178.04M | 167.25M | 158.53M | 144.90M |
| Average Diluted Shares Outstanding | 186.32M | 178.04M | 167.25M | 158.53M | 144.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |